162 related articles for article (PubMed ID: 24263123)
1. Renal and hormonal effects of systemic nitric oxide inhibition in patients with congestive heart failure and in healthy control subjects.
Bech JN; Starklint J; Bentzen H; Nyvad O; Pedersen EB
J Card Fail; 2013 Nov; 19(11):776-85. PubMed ID: 24263123
[TBL] [Abstract][Full Text] [Related]
2. Enhanced sodium retention after acute nitric oxide blockade in mildly sodium loaded patients with essential hypertension.
Bech JN; Nielsen EH; Pedersen RS; Svendsen KB; Pedersen EB
Am J Hypertens; 2007 Mar; 20(3):287-95. PubMed ID: 17324742
[TBL] [Abstract][Full Text] [Related]
3. Renal effects of NO-inhibition in patients with cirrhosis vs. healthy controls: a randomized placebo-controlled crossover study.
Bech JN; Aagaard NK; Pedersen RS; Sorensen TB; Vilstrup H; Pedersen EB
Liver Int; 2014 Feb; 34(2):211-9. PubMed ID: 23809512
[TBL] [Abstract][Full Text] [Related]
4. Hemodynamic, renal, and endocrine effects of acute inhibition of nitric oxide synthase in compensated cirrhosis.
La Villa G; Barletta G; Pantaleo P; Del Bene R; Vizzutti F; Vecchiarino S; Masini E; Perfetto F; Tarquini R; Gentilini P; Laffi G
Hepatology; 2001 Jul; 34(1):19-27. PubMed ID: 11431729
[TBL] [Abstract][Full Text] [Related]
5. Effects of systemic NO synthesis inhibition on RPF, GFR, UNa, and vasoactive hormones in healthy humans.
Bech JN; Nielsen CB; Pedersen EB
Am J Physiol; 1996 May; 270(5 Pt 2):F845-51. PubMed ID: 8928847
[TBL] [Abstract][Full Text] [Related]
6. Rapid non-genomic effects of aldosterone on the renal vasculature.
Schmidt BM
Steroids; 2008 Oct; 73(9-10):961-5. PubMed ID: 18242654
[TBL] [Abstract][Full Text] [Related]
7. Effect of nebivolol on renal nitric oxide availability and tubular function in patients with essential hypertension.
Mose FH; Jensen JM; Therwani S; Mortensen J; Hansen AB; Bech JN; Pedersen EB
Br J Clin Pharmacol; 2015 Sep; 80(3):425-35. PubMed ID: 25778445
[TBL] [Abstract][Full Text] [Related]
8. Effect of atorvastatin on renal NO availability and tubular function in patients with stage II-III chronic kidney disease and type 2 diabetes.
Mose FH; Larsen T; Jensen JM; Hansen AB; Bech JN; Pedersen EB
Scand J Clin Lab Invest; 2014 Jan; 74(1):8-19. PubMed ID: 24256611
[TBL] [Abstract][Full Text] [Related]
9. Nitric oxide synthesis inhibition does not impair water immersion-induced renal vasodilation in humans.
Dijkhorst-Oei LT; Boer P; Rabelink TJ; Koomans HA
J Am Soc Nephrol; 2000 Jul; 11(7):1293-1302. PubMed ID: 10864586
[TBL] [Abstract][Full Text] [Related]
10. Acute renal haemodynamic effects of glucagon-like peptide-1 receptor agonist exenatide in healthy overweight men.
Muskiet MH; Tonneijck L; Smits MM; Kramer MH; Diamant M; Joles JA; van Raalte DH
Diabetes Obes Metab; 2016 Feb; 18(2):178-85. PubMed ID: 26636423
[TBL] [Abstract][Full Text] [Related]
11. Chronic administration of phosphodiesterase type 5 inhibitor suppresses renal production of endothelin-1 in dogs with congestive heart failure.
Yamamoto T; Wada A; Ohnishi M; Tsutamoto T; Fujii M; Matsumoto T; Takayama T; Wang X; Kurokawa K; Kinoshita M
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():258S-262S. PubMed ID: 12193099
[TBL] [Abstract][Full Text] [Related]
12. Contribution of endogenous nitric oxide to basal vasomotor tone of peripheral vessels and plasma B-type natriuretic peptide levels in patients with congestive heart failure.
Ishibashi Y; Shimada T; Sakane T; Takahashi N; Sugamori T; Ohhata S; Inoue S; Katoh H; Sano K; Murakami Y; Hashimoto M
J Am Coll Cardiol; 2000 Nov; 36(5):1605-11. PubMed ID: 11079665
[TBL] [Abstract][Full Text] [Related]
13. Dietary sodium affects systemic and renal hemodynamic response to NO inhibition in healthy humans.
Bech JN; Nielsen CB; Ivarsen P; Jensen KT; Pedersen EB
Am J Physiol; 1998 May; 274(5):F914-23. PubMed ID: 9612329
[TBL] [Abstract][Full Text] [Related]
14. The renal and systemic hemodynamic effects of a nitric oxide-synthase inhibitor are reversed by a selective endothelin(a) receptor antagonist in men.
Schmidt A; Bayerle-Eder M; Pleiner H; Zeisner C; Wolzt M; Mayer G; Schmetterer L
Nitric Oxide; 2001 Aug; 5(4):370-6. PubMed ID: 11485375
[TBL] [Abstract][Full Text] [Related]
15. The systemic and renal response to NO inhibition is not modified by angiotensin-II-receptor blockade in healthy humans.
Bech JN; Svendsen KB; Nielsen CB; Pedersen EB
Nephrol Dial Transplant; 1999 Mar; 14(3):641-7. PubMed ID: 10193813
[TBL] [Abstract][Full Text] [Related]
16. Effects of exogenous and endogenous natriuretic peptides on forearm vascular function in chronic heart failure.
Schmitt M; Gunaruwan P; Payne N; Taylor J; Lee L; Broadley AJ; Nightingale AK; Cockcroft JR; Struthers AD; Tyberg JV; Frenneaux MP
Arterioscler Thromb Vasc Biol; 2004 May; 24(5):911-7. PubMed ID: 15001459
[TBL] [Abstract][Full Text] [Related]
17. Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?
Schlaich MP; Jacobi J; John S; Delles C; Fleischmann I; Schmieder RE
Clin Sci (Lond); 2000 Oct; 99(4):293-302. PubMed ID: 10995594
[TBL] [Abstract][Full Text] [Related]
18. Effects of nitric oxide inhibition on basal forearm blood flow in patients with nonischemic chronic heart failure.
Yoshida H; Nakamura M; Akatsu T; Arakawa N; Hiramori K
Heart Vessels; 1998; 13(3):142-6. PubMed ID: 10328184
[TBL] [Abstract][Full Text] [Related]
19. Assessment of endothelial function of the renal vasculature in human subjects.
Delles C; Jacobi J; Schlaich MP; John S; Schmieder RE
Am J Hypertens; 2002 Jan; 15(1 Pt 1):3-9. PubMed ID: 11824856
[TBL] [Abstract][Full Text] [Related]
20. Rapid nongenomic effects of aldosterone on the renal vasculature in humans.
Schmidt BM; Sammer U; Fleischmann I; Schlaich M; Delles C; Schmieder RE
Hypertension; 2006 Apr; 47(4):650-5. PubMed ID: 16520409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
